Sitagliptin Metformin Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Dongkook Pharmaceutical Co., Ltd.
MFDS item code 202200617 · Approved 2022.02.08 · Insurance code 653405210
Improvement of glycemic control in type 2 diabetes
This medication is used in conjunction with diet and exercise to help improve blood glucose control in patients with type 2 diabetes. It is effective for those who have not previously received diabetes medication or have difficulty managing blood glucose with monotherapy. It is also helpful when blood glucose control is insufficient with monotherapy of metformin or sitagliptin. This medication can enhance therapeutic effects when used together with various other diabetes medications when blood glucose is not adequately controlled. It also contributes to improved blood glucose control when used in combination with insulin. It is used to enhance blood glucose control across various treatment stages.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's existing metformin dose. - Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients Who Must Not Receive This Drug).
This medication contains both sitagliptin and metformin and is used to help control blood glucose in patients with type 2 diabetes. While taking this medication, there may be a risk of severe hypersensitivity reactions, so if any allergic symptoms, skin rashes, or breathing difficulties occur, you should immediately stop taking it and seek medical attention. Acute pancreatitis may occur, so you should inform your doctor if you experience symptoms such as abdominal pain, vomiting, or loss of appetite. Patients with severe renal impairment or acute heart failure, acute myocardial infarction, or severe infection should not take this medication, and it may need to be temporarily discontinued before and after surgery. Women who are pregnant or may become pregnant, and breastfeeding women should avoid taking this medication for safety. This medication may cause hypoglycemia; therefore, it is important to have regular meals and be cautious during intense exercise. When used in combination with other hypoglycemic agents, the risk of hypoglycemia may increase, so dosage adjustments according to a doctor's instructions are necessary. Alcohol consumption may increase the risk of lactic acidosis; therefore, alcohol should be avoided while taking this medication. Regular renal function tests are needed as there may be a decrease in renal function, and blood tests are recommended as vitamin B12 deficiency may occur. Additionally, if any unusual symptoms such as blistering of the skin or severe joint pain occur while on medication, you should consult a doctor immediately. There may be drug interactions; therefore, if you are taking other medications, you must inform your doctor or pharmacist, and you should notify medical personnel immediately if any unusual symptoms develop during medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is not exposed to air, at a temperature between 1 and 30 degrees Celsius. Storing it this way maintains the medication's effectiveness and prevents deterioration.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Dongkook Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.